Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

5 articles from the last 7 days matching "mutations"

ResearchBIORXIVToday

Preprint: Genotype-Based Severity Scoring System in Wolfram Syndrome

Wolfram syndrome is a rare genetic disorder that causes diabetes, vision loss, hearing loss, and brain problems. Researchers created a new scoring system that looks at the specific genetic mutations in the WFS1 gene to predict how severe a patient's symptoms will be and when they might appear. This system could help doctors understand what to expect for each patient based on their individual genetic makeup.

WHY IT MATTERSIf validated, this genotype-based scoring system could allow doctors to predict disease progression and symptom onset in individual Wolfram syndrome patients, enabling earlier intervention and personalized monitoring strategies.
Good to knowWolfram syndromeRead →
Clinical trialCLINICALTRIALSToday

Trial Now Recruiting: A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (NCT06010329)

Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.

WHY IT MATTERSIf you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.
You can act on thisnon-small cell lung cancerlocally advanced non-small cell lung cancermetastatic non-small cell lung cancerRead →
Clinical trialCLINICALTRIALSToday

Trial Now Recruiting: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (NCT06706076)

Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.

WHY IT MATTERSThis trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.
You can act on thisnon-small cell lung cancer (NSCLC)locally advanced NSCLCmetastatic NSCLCRead →
ResearchRSS3 days ago

Spontaneous mutations may underlie some sporadic ALS cases

Scientists discovered that some people with ALS (a disease that affects nerve cells controlling muscles) may develop the condition from new mutations that happen by chance in their nerve cells, rather than inheriting the mutation from their parents. This is different from inherited ALS cases where a parent passes down a faulty gene. This finding suggests there are multiple ways ALS can develop, which could help doctors better understand and treat the disease.

WHY IT MATTERSIf your ALS diagnosis is sporadic (not inherited), this research suggests your condition may have developed from random mutations in your nerve cells rather than a genetic predisposition, which could change how doctors approach your treatment and genetic counseling.
Good to knowAmyotrophic Lateral Sclerosis (ALS)Read →
Clinical trialCLINICALTRIALS3 days ago

Trial Now Recruiting: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. (NCT06563999)

Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.

WHY IT MATTERSIf you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
You can act on thisNon-small-cell lung cancer (NSCLC), stage III, unresectableRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases